Imaging Butyrylcholinesterase in Multiple Sclerosis.
Autoradiography
Butyrylcholinesterase
Molecular imaging
Multiple sclerosis
Journal
Molecular imaging and biology
ISSN: 1860-2002
Titre abrégé: Mol Imaging Biol
Pays: United States
ID NLM: 101125610
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
13
06
2020
accepted:
01
09
2020
revised:
30
07
2020
pubmed:
15
9
2020
medline:
26
8
2021
entrez:
14
9
2020
Statut:
ppublish
Résumé
Molecular imaging agents targeting butyrylcholinesterase (BChE) have shown promise in other neurodegenerative disorders and may have utility in detecting changes to normal appearing white matter in multiple sclerosis (MS). BChE activity is present in white matter and localizes to activated microglia associated with MS lesions. The purpose of this study was to further characterize changes in the cholinergic system in MS pathology, and to explore the utility of BChE radioligands as potential diagnostic and treatment monitoring agents in MS. Cortical and white matter lesions were identified using myelin staining, and lesions were classified based on microglial activation patterns. Adjacent brain sections were used for cholinesterase histochemistry and in vitro autoradiography using phenyl 4-[ BChE activity is positively correlated with microglial activation in white matter MS lesions. There is no alteration in cholinesterase activity in cortical MS lesions. BChE imaging agents have the potential to detect MS lesions and subtle pathology in normal-appearing white matter in postmortem MS brain tissue. The possibility of BChE imaging agents serving to supplement current diagnostic and treatment monitoring strategies should be evaluated.
Identifiants
pubmed: 32926288
doi: 10.1007/s11307-020-01540-6
pii: 10.1007/s11307-020-01540-6
doi:
Substances chimiques
Phenylcarbamates
0
phenyl 4-iodophenylcarbamate
0
Acetylcholinesterase
EC 3.1.1.7
Butyrylcholinesterase
EC 3.1.1.8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
127-138Subventions
Organisme : CIHR
ID : PJT-153319
Pays : Canada
Références
Bö L, Mörk S, Kong PA, Nyland H, Pardo CA, Trapp BD (1994) Detection of MHC class II-antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions. J Neuroimmunol 51:135–146
pubmed: 8182113
Bitsch A, Schuchardt J, Bunkowski S et al (2000) Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain J Neurol 123(Pt 6):1174–1183
Kutzelnigg A, Lucchinetti CF, Stadelmann C, Brück W, Rauschka H, Bergmann M, Schmidbauer M, Parisi JE, Lassmann H (2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain J Neurol 128:2705–2712
Gold R, Linington C, Lassmann H (2006) Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain J Neurol 129:1953–1971
Sanabria-Castro A, Flores-Díaz M, Alape-Girón A (2019) Biological models in multiple sclerosis. J Neurosci Res 00:1–18
Brownlee WJ, Miller DH (2014) Clinically isolated syndromes and the relationship to multiple sclerosis. J Clin Neurosci 21:2065–2071
pubmed: 25027666
Eran A, García M, Malouf R, Bosak N, Wagner R, Ganelin-Cohen E, Artsy E, Shifrin A, Rozenberg A (2018) MRI in predicting conversion to multiple sclerosis within 1 year. Brain Behav 8:e01042
pubmed: 30073779
pmcid: 6160649
Lublin FD (2014) New multiple sclerosis phenotypic classification. Eur Neurol 72(Suppl 1):1–5
pubmed: 25278115
Filippi M, Rocca MA, Ciccarelli O, de Stefano N, Evangelou N, Kappos L, Rovira A, Sastre-Garriga J, Tintorè M, Frederiksen JL, Gasperini C, Palace J, Reich DS, Banwell B, Montalban X, Barkhof F, MAGNIMS Study Group (2016) MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 15:292–303
pubmed: 26822746
pmcid: 4760851
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162–173
pubmed: 29275977
Wattjes MP, Rovira À, Miller D, Yousry TA, Sormani MP, de Stefano MP, Tintoré M, Auger C, Tur C, Filippi M, Rocca MA, Fazekas F, Kappos L, Polman C, Frederik Barkhof, Xavier Montalban, MAGNIMS study group (2015) Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients. Nat Rev Neurol 11:597–606
pubmed: 26369511
Traboulsee A, Simon JH, Stone L, Fisher E, Jones DE, Malhotra A, Newsome SD, Oh J, Reich DS, Richert N, Rammohan K, Khan O, Radue EW, Ford C, Halper J, Li D (2016) Revised recommendations of the Consortium of MS Centers Task Force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of multiple sclerosis. AJNR Am J Neuroradiol 37:394–401
pubmed: 26564433
Filippi M, Preziosa P, Meani A, Ciccarelli O, Mesaros S, Rovira A, Frederiksen J, Enzinger C, Barkhof F, Gasperini C, Brownlee W, Drulovic J, Montalban X, Cramer SP, Pichler A, Hagens M, Ruggieri S, Martinelli V, Miszkiel K, Tintorè M, Comi G, Dekker I, Uitdehaag B, Dujmovic-Basuroski I, Rocca MA (2018) Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. Lancet Neurol 17:133–142
pubmed: 29275979
Gaetani L, Prosperini L, Mancini A, Eusebi P, Cerri MC, Pozzilli C, Calabresi P, Sarchielli P, di Filippo M (2018) 2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes. J Neurol 265:2684–2687
pubmed: 30196327
Filippi M (2015) MRI measures of neurodegeneration in multiple sclerosis: implications for disability, disease monitoring, and treatment. J Neurol 262:1–6
pubmed: 24723117
De Santis S, Granberg T, Ouellette R et al (2019) Evidence of early microstructural white matter abnormalities in multiple sclerosis from multi-shell diffusion MRI. NeuroImage Clin 22:101699
pubmed: 30739842
pmcid: 6370560
Silver A (1974) The biology of cholinesterases. North-Holland Pub. Co.; American Elsevier Pub. Co., Amsterdam; New York
Li B, Stribley JA, Ticu A, Xie W, Schopfer LM, Hammond P, Brimijoin S, Hinrichs SH, Lockridge O (2000) Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse. J Neurochem 75:1320–1331
pubmed: 10936216
pmcid: 10936216
Mesulam M-M, Guillozet A, Shaw P, Quinn B (2002) Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 9:88–93
pubmed: 11848688
Mesulam MM (2009) Acetylcholine neurotransmission in CNS. In: Squire LR (ed) Encyclopedia of neuroscience. Academic Press, Oxford, pp 1–4
Mesulam M-M, Mufson EJ, Levey AI, Wainer BH (1983) Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (Substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol 214:170–197
pubmed: 6841683
Selden NR, Gitelman DR, Salamon-Murayama N et al (1998) Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain J Neurol 121(Pt 12):2249–2257
Darvesh S, Grantham DL, Hopkins DA (1998) Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation. J Comp Neurol 393:374–390
pubmed: 9548556
Darvesh S, Hopkins DA (2003) Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. J Comp Neurol 463:25–43
pubmed: 12811800
Darvesh S, Leblanc AM, Macdonald IR et al (2010) Butyrylcholinesterase activity in multiple sclerosis neuropathology. Chem Biol Interact 187:425–431
pubmed: 20122907
Guillozet AL, Smiley JF, Mash DC, Mesulam MM (1997) Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 42:909–918
pubmed: 9403484
Darvesh S, Hopkins DA, Geula C (2003) Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 4:131–138
pubmed: 12563284
Ballard CG, Greig NH, Guillozet-Bongaarts AL, Enz A, Darvesh S (2005) Cholinesterases: roles in the brain during health and disease. Curr Alzheimer Res 2:307–318
pubmed: 15974896
Darvesh S (2013) Butyrylcholinesterase radioligands to image Alzheimer’s disease brain. Chem Biol Interact 203:354–357
pubmed: 22935510
Darvesh S (2016) Butyrylcholinesterase as a diagnostic and therapeutic target for Alzheimer’s disease. Curr Alzheimer Res 13:1173–1177
pubmed: 27040140
DeBay DR, Reid GA, Pottie IR et al (2017) Targeting butyrylcholinesterase for preclinical single photon emission computed tomography (SPECT) imaging of Alzheimer’s disease. Alzheimers Dement N Y N 3:166–176
DeBay DR, Pottie I, Reid AG et al (2019) P2-402 [abstract]: Synthesis and in vivo brain pet evaluation of 1-methyl-4-piperidyl p-18[f]flourobenzoate (trv6501): a butyrylcholinesterase-specific radioligand for Alzheimer’s disease. Alzheimer’s Association International Conference 2019, Los Angeles, CA. Alzheimers Dement 15:P760
Macdonald IR, Reid GA, Pottie IR et al (2016) Synthesis and preliminary evaluation of phenyl 4-123I-iodophenylcarbamate for visualization of cholinesterases associated with Alzheimer disease pathology. J Nucl Med 57:297–302
pubmed: 26541777
Pottie IR, Higgins EA, Blackman RA, Macdonald IR, Martin E, Darvesh S (2011) Cysteine thioesters as myelin proteolipid protein analogues to examine the role of butyrylcholinesterase in myelin decompaction. ACS Chem Neurosci 2:151–159
pubmed: 22778864
Caprariello AV, Rogers JA, Morgan ML, Hoghooghi V, Plemel JR, Koebel A, Tsutsui S, Dunn JF, Kotra LP, Ousman SS, Wee Yong V, Stys PK (2018) Biochemically altered myelin triggers autoimmune demyelination. Proc Natl Acad Sci 115:5528–5533
pubmed: 29728463
Macdonald IR, Maxwell SP, Reid GA, Cash MK, DeBay DR, Darvesh S (2017) Quantification of butyrylcholinesterase activity as a sensitive and specific biomarker of Alzheimer’s disease. J Alzheimers Dis 58:491–505
pubmed: 28453492
pmcid: 5438481
Bø L, Vedeler CA, Nyland H, Trapp BD, Mørk SJ (2003) Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler Houndmills Basingstoke Engl 9:323–331
Lassmann H, Brück W, Lucchinetti CF (2007) The immunopathology of multiple sclerosis: an overview. Brain Pathol 17:210–218
pubmed: 17388952
Calabrese M, Filippi M, Gallo P (2010) Cortical lesions in multiple sclerosis. Nat Rev Neurol 6:438–444
pubmed: 20625376
Calabrese M, Magliozzi R, Ciccarelli O, Geurts JJG, Reynolds R, Martin R (2015) Exploring the origins of grey matter damage in multiple sclerosis. Nat Rev Neurosci 16:147–158
pubmed: 25697158
Prins M, Schul E, Geurts J, van der Valk P, Drukarch B, van Dam AM (2015) Pathological differences between white and grey matter multiple sclerosis lesions. Ann N Y Acad Sci 1351:99–113
pubmed: 26200258
Duncan ID, Hammang JP, Goda S, Quarles RH (1989) Myelination in the jimpy mouse in the absence of proteolipid protein. Glia 2:148–154
pubmed: 2526078
Di Bari M, Di Pinto G, Reale M et al (2017) Cholinergic system and neuroinflammation: implication in multiple sclerosis. Cent Nerv Syst Agents Med Chem 17:109–115
pubmed: 27550615
Hoover DB (2017) Cholinergic modulation of the immune system presents new approaches for treating inflammation. Pharmacol Ther 179:1–16
pubmed: 28529069
pmcid: 5651192
Di Pinto G, Di Bari M, Martin-Alvarez R et al (2018) Comparative study of the expression of cholinergic system components in the CNS of experimental autoimmune encephalomyelitis mice: acute vs remitting phase. Eur J Neurosci 48:2165–2181
pubmed: 30144326
Reale M, de Angelis F, di Nicola M, Capello E, di Ioia M, Luca G, Lugaresi A, Tata A (2012) Relation between pro-inflammatory cytokines and acetylcholine levels in relapsing-remitting multiple sclerosis patients. Int J Mol Sci 13:12656–12664
pubmed: 23202919
pmcid: 3497293
Reale M, Costantini E, Di Nicola M et al (2018) Butyrylcholinesterase and acetylcholinesterase polymorphisms in multiple sclerosis patients: implication in peripheral inflammation. Sci Rep 8:1319
pubmed: 29358722
pmcid: 5778050
Pavlov VA, Tracey KJ (2006) Controlling inflammation: the cholinergic anti-inflammatory pathway. Biochem Soc Trans 34:1037–1040
pubmed: 17073745
Di Bari M, Reale M, Di Nicola M et al (2016) Dysregulated homeostasis of acetylcholine levels in immune cells of RR-multiple sclerosis patients. Int J Mol Sci 17(12):2009
pmcid: 5187809
Bauckneht M, Capitanio S, Raffa S, Roccatagliata L, Pardini M, Lapucci C, Marini C, Sambuceti G, Inglese M, Gallo P, Cecchin D, Nobili F, Morbelli S (2019) Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers. EJNMMI Radiopharm Chem 4(1):6
pubmed: 31659498
pmcid: 6453990
Rissanen E, Tuisku J, Rokka J et al (2014) In vivo detection of diffuse inflammation in secondary progressive multiple sclerosis using PET imaging and the radioligand
pubmed: 24711650
Datta G, Colasanti A, Kalk N et al (2017) 11C-PBR28 and 18F-PBR111 detect white matter inflammatory heterogeneity in multiple sclerosis. J Nucl Med 58:1477–1482
pubmed: 28302760
Högel H, Rissanen E, Vuorimaa A, Airas L (2018) Positron emission tomography imaging in evaluation of MS pathology in vivo. Mult Scler J 24:1399–1412
Bohnen NI, Grothe MJ, Ray NJ, Müller MLTM, Teipel SJ (2018) Recent advances in cholinergic imaging and cognitive decline-revisiting the cholinergic hypothesis of dementia. Curr Geriatr Rep 7:1–11
pubmed: 29503795
pmcid: 5831510
Bohnen NI, Kanel P, Müller MLTM (2018) Molecular imaging of the cholinergic system in Parkinson’s disease. Int Rev Neurobiol 141:211–250
pubmed: 30314597
pmcid: 6218162
Roy R, Niccolini F, Pagano G, Politis M (2016) Cholinergic imaging in dementia spectrum disorders. Eur J Nucl Med Mol Imaging 43:1376–1386
pubmed: 26984612
pmcid: 4865532